Company Name Kringle Pharma, Inc.
Established December 21, 2001
Capital 200 million JPY
Main Banks Mizuho Bank, Ltd., The Bank of Tokyo-Mitsubishi UFJ, Ltd.
Major Stockholders Keio Innovation Initiative, Inc.
Nippon Zenyaku Kogyo Co., Ltd.
DBJ Capital Co., Ltd.
Company Mission Our company mission is to save the patients suffering from cancer and incurable diseases by offering a new method of treatment derived from the innovative research and development of HGF and NK4.
Main Project Research & development of HGF (pharmaceuticals for regenerative medicine)
Research & development of NK4 (pharmaceuticals for cancer therapy)
Access


Copyright (C)2004-2011 Kringle Pharma, Inc. All rights reserved.